Chandigarh-based pharmaceutical major Ind-Swift Laboratories is all set to start its manufacturing facility in the US and make a foray into the Japanese drug market.
Ind-Swift Laboratories has completed United State Federal Drug Authority (USFDA) inspection for its Clarithromycin active pharmaceutical ingredient (API) manufacturing unit, its managing director N.R. Munjal said here Thursday.
Clarithromycin is a macrolide antibiotic molecule used in the treatment of the lower respiratory tract infections.
Munjal said the inspection would help the company roll out its APIs in the North American market. Macrolides have a world market size of US$1.3 billion and Ind-Swift is the second largest manufacturer of the medicine. The US is the biggest generic drug market in the world.
He said Ind-Swift was also tying up with top US based generic and biotechnology companies for its future expansion plans in North America, adding that the company was at an advanced stage of entering the Japanese drug market.